Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA
→ With its shares boosted by news of swelling revenue from its eteplirsen franchise in Duchenne muscular dystrophy, Sarepta has priced shares $SRPT for a $325 million raise. The biotech says it plans to use the cash for a variety of purposes, ranging from commercialization efforts to business development and clinical trials.
→ Astellas has joined the global migration of biopharma companies to Cambridge, MA. The Japanese pharma has taken a lease out on space in Cambridge, according to a report from the Boston Business Journal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.